Neuropathic pain therapeutic - Boehringer Ingelheim

Drug Profile

Neuropathic pain therapeutic - Boehringer Ingelheim

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim; Evotec AG
  • Developer Boehringer Ingelheim
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Neuropathic pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Neuropathic-pain in Germany
  • 31 May 2011 Boehringer Ingelheim and Evotec initiate a phase I trial of its back-up neuropathic pain therapeutic in Germany
  • 20 May 2010 Phase-I clinical trials in Neuropathic pain in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top